{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:07:52Z","timestamp":1791994072442,"version":"4.4.0"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["P20GM104932"],"award-info":[{"award-number":["P20GM104932"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["C06RR14503"],"award-info":[{"award-number":["C06RR14503"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003187","name":"NSF","doi-asserted-by":"publisher","award":["1338056"],"award-info":[{"award-number":["1338056"]}],"id":[{"id":"10.13039\/100003187","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.bcp.2018.06.024","type":"journal-article","created":{"date-parts":[[2018,6,26]],"date-time":"2018-06-26T21:11:50Z","timestamp":1530047510000},"page":"82-91","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Interactions of endocannabinoid virodhamine and related analogs with human monoamine oxidase-A and -B"],"prefix":"10.1016","volume":"155","author":[{"given":"Pankaj","family":"Pandey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narayan D.","family":"Chaurasiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babu L.","family":"Tekwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Doerksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 1","key":"10.1016\/j.bcp.2018.06.024_b0005","doi-asserted-by":"crossref","first-page":"S287","DOI":"10.1038\/sj.bjp.0706464","article-title":"Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness","volume":"147","author":"Youdim","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2018.06.024_b0010","first-page":"1","article-title":"Kinetics, mechanism, and inhibition of monoamine oxidase","author":"Ramsay","year":"2018","journal-title":"J. Neural Transm."},{"issue":"13","key":"10.1016\/j.bcp.2018.06.024_b0015","doi-asserted-by":"crossref","first-page":"4934","DOI":"10.1073\/pnas.85.13.4934","article-title":"cDNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties","volume":"85","author":"Bach","year":"1988","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"4","key":"10.1016\/j.bcp.2018.06.024_b0020","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nrn1883","article-title":"The therapeutic potential of monoamine oxidase inhibitors","volume":"7","author":"Youdim","year":"2006","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.bcp.2018.06.024_b0025","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ejmech.2018.01.003","article-title":"Privileged scaffolds as MAO inhibitors: retrospect and prospects","volume":"145","author":"Tripathi","year":"2018","journal-title":"Eur. J. Med. Chem."},{"issue":"10","key":"10.1016\/j.bcp.2018.06.024_b0030","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1017\/S1092852900016965","article-title":"Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants","volume":"13","author":"Stahl","year":"2008","journal-title":"CNS Spectr."},{"issue":"3","key":"10.1016\/j.bcp.2018.06.024_b0035","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/13543776.2018.1427735","article-title":"MAO inhibitors and their wider applications: a patent review","volume":"28","author":"Carradori","year":"2018","journal-title":"Expert Opin. Ther. Pat."},{"issue":"11","key":"10.1016\/j.bcp.2018.06.024_b0040","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1111\/j.1468-1331.2006.01547.x","article-title":"Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's disease","volume":"13","author":"Horstink","year":"2006","journal-title":"Eur. J. Neurol."},{"issue":"3","key":"10.1016\/j.bcp.2018.06.024_b0045","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.drudis.2018.01.033","article-title":"Safinamide: a new hope for Parkinson's disease?","volume":"23","author":"Teixeira","year":"2018","journal-title":"Drug Discovery Today"},{"issue":"1\u20132","key":"10.1016\/j.bcp.2018.06.024_b0050","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0161-813X(03)00106-2","article-title":"Monoamine oxidase-B inhibition in Alzheimer\u2019s disease","volume":"25","author":"Riederer","year":"2004","journal-title":"Neurotoxicology"},{"issue":"7","key":"10.1016\/j.bcp.2018.06.024_b0055","first-page":"672","article-title":"The endocannabinoid system: a drug discovery perspective","volume":"6","author":"Piomelli","year":"2005","journal-title":"Curr. Opin Invest. Drugs"},{"issue":"3","key":"10.1016\/j.bcp.2018.06.024_b0060","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1124\/pr.58.3.2","article-title":"The endocannabinoid system as an emerging target of pharmacotherapy","volume":"58","author":"Pacher","year":"2006","journal-title":"Pharmacol. Rev."},{"issue":"4","key":"10.1016\/j.bcp.2018.06.024_b0065","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1124\/pr.110.003004","article-title":"International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2","volume":"62","author":"Pertwee","year":"2010","journal-title":"Pharmacol. Rev."},{"issue":"11","key":"10.1016\/j.bcp.2018.06.024_b0070","doi-asserted-by":"crossref","first-page":"17078","DOI":"10.3390\/molecules191117078","article-title":"Endocannabinoids, related compounds and their metabolic routes","volume":"19","author":"Fezza","year":"2014","journal-title":"Molecules"},{"issue":"5","key":"10.1016\/j.bcp.2018.06.024_b0075","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1007\/s00210-004-0921-x","article-title":"Differential effects of acute cannabinoid drug treatment, mediated by CB1 receptors, on the in vivo activity of tyrosine and tryptophan hydroxylase in the rat brain","volume":"369","author":"Moranta","year":"2004","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"issue":"6","key":"10.1016\/j.bcp.2018.06.024_b0080","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00210-010-0517-6","article-title":"Inhibition of monoamine oxidase activity by cannabinoids","volume":"381","author":"Fisar","year":"2010","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"issue":"9","key":"10.1016\/j.bcp.2018.06.024_b0085","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1038\/sj.npp.1301330","article-title":"Cellular mechanisms underlying the anxiolytic effect of low doses of peripheral Delta9-tetrahydrocannabinol in rats","volume":"32","author":"Rubino","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bcp.2018.06.024_b0090","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/3-540-26573-2_11","article-title":"Effects of cannabinoids on neurotransmission","volume":"168","author":"Szabo","year":"2005","journal-title":"Handb. Exp. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2018.06.024_b0095","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1124\/jpet.105.092718","article-title":"Effects of exogenous and endogenous cannabinoids on GABAergic neurotransmission between the caudate-putamen and the globus pallidus in the mouse","volume":"316","author":"Engler","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"14","key":"10.1016\/j.bcp.2018.06.024_b0100","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.2174\/138161209788168029","article-title":"Endocannabinoids in the treatment of mood disorders: evidence from animal models","volume":"15","author":"Bambico","year":"2009","journal-title":"Curr. Pharm. Des."},{"issue":"1","key":"10.1016\/j.bcp.2018.06.024_b0105","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.bbrc.2007.09.107","article-title":"Cannabinoid receptor agonists are mitochondrial inhibitors: a unified hypothesis of how cannabinoids modulate mitochondrial function and induce cell death","volume":"364","author":"Athanasiou","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"12","key":"10.1016\/j.bcp.2018.06.024_b0110","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1007\/s00702-008-0131-7","article-title":"Differential effects of the antidepressants tranylcypromine and fluoxetine on limbic cannabinoid receptor binding and endocannabinoid contents","volume":"115","author":"Hill","year":"2008","journal-title":"J. Neural Transm. (Vienna)"},{"issue":"2","key":"10.1016\/j.bcp.2018.06.024_b0115","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/hipo.20386","article-title":"Prolonged glucocorticoid treatment decreases cannabinoid CB1 receptor density in the hippocampus","volume":"18","author":"Hill","year":"2008","journal-title":"Hippocampus"},{"issue":"1","key":"10.1016\/j.bcp.2018.06.024_b0120","first-page":"15","article-title":"Effect of cannabinoids on the activity of monoamine oxidase in normal human platelets","volume":"90","author":"Mazor","year":"1982","journal-title":"Arch. Int. Physiol. Biochim."},{"issue":"4","key":"10.1016\/j.bcp.2018.06.024_b0125","first-page":"482","article-title":"Effect of delta 9-tetrahydrocannabinol on monoamine oxidase activity in bovine eye tissues, in vitro","volume":"22","author":"Gawienowski","year":"1982","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"3","key":"10.1016\/j.bcp.2018.06.024_b0130","first-page":"471","article-title":"Acute and chronic effects of tetrahydrocannabinols on monoamide oxidase activity: possible vehicle\/tetrahydrocannabinol interactions","volume":"17","author":"Clarke","year":"1977","journal-title":"Res. Commun. Chem. Pathol. Pharmacol."},{"issue":"3","key":"10.1016\/j.bcp.2018.06.024_b0135","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1124\/jpet.301.3.1020","article-title":"Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor","volume":"301","author":"Porter","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"7","key":"10.1016\/j.bcp.2018.06.024_b0140","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1211\/0022357023682","article-title":"Vasorelaxant activities of the putative endocannabinoid virodhamine in rat isolated small mesenteric artery","volume":"56","author":"Ho","year":"2004","journal-title":"J. Pharm. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2018.06.024_b0145","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.pharmthera.2014.02.010","article-title":"Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: focus on modulation of CNS monoamine neurotransmitter release","volume":"143","author":"Finberg","year":"2014","journal-title":"Pharmacol. Ther."},{"issue":"10","key":"10.1016\/j.bcp.2018.06.024_b0150","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1021\/acs.jnatprod.6b00440","article-title":"Isolation of acacetin from calea urticifolia with inhibitory properties against human monoamine oxidase-A and -B","volume":"79","author":"Chaurasiya","year":"2016","journal-title":"J Nat. Prod."},{"key":"10.1016\/j.bcp.2018.06.024_b0155","first-page":"S02T081R2","article-title":"A fluorescent-based, high-throughput assay for detecting inhibitors of human Monoamine Oxidase A and B","author":"Parikh","year":"2012","journal-title":"BD Biosci. Discovery Labware"},{"issue":"6","key":"10.1016\/j.bcp.2018.06.024_b0160","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1177\/2472555217698677","article-title":"A combined in vitro assay for evaluation of neurotrophic activity and cytotoxicity","volume":"22","author":"Chaurasiya","year":"2017","journal-title":"SLAS Discov."},{"issue":"15","key":"10.1016\/j.bcp.2018.06.024_b0165","doi-asserted-by":"crossref","first-page":"5739","DOI":"10.1073\/pnas.0710626105","article-title":"Structure of human monoamine oxidase A at 2.2-A resolution: the control of opening the entry for substrates\/inhibitors","volume":"105","author":"Son","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"17","key":"10.1016\/j.bcp.2018.06.024_b0170","doi-asserted-by":"crossref","first-page":"9750","DOI":"10.1073\/pnas.1633804100","article-title":"Insights into the mode of inhibition of human mitochondrial monoamine oxidase B from high-resolution crystal structures","volume":"100","author":"Binda","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.bcp.2018.06.024_b0175","unstructured":"Schr\u00f6dinger Release 2016-2: Maestro, LLC, New York, NY, 2016."},{"issue":"47","key":"10.1016\/j.bcp.2018.06.024_b0180","doi-asserted-by":"crossref","first-page":"36849","DOI":"10.1074\/jbc.M110.169482","article-title":"Potentiation of ligand binding through cooperative effects in monoamine oxidase B","volume":"285","author":"Bonivento","year":"2010","journal-title":"J. Biol. Chem."},{"issue":"7","key":"10.1016\/j.bcp.2018.06.024_b0185","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1021\/jm031087c","article-title":"Crystal structures of monoamine oxidase B in complex with four inhibitors of the N-propargylaminoindan class","volume":"47","author":"Binda","year":"2004","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2018.06.024_b0190","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1021\/ml200196p","article-title":"Molecular insights into human monoamine oxidase B inhibition by the glitazone anti-diabetes drugs","volume":"3","author":"Binda","year":"2011","journal-title":"ACS Med. Chem. Lett."},{"issue":"23","key":"10.1016\/j.bcp.2018.06.024_b0195","doi-asserted-by":"crossref","first-page":"5848","DOI":"10.1021\/jm070677y","article-title":"Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs","volume":"50","author":"Binda","year":"2007","journal-title":"J. Med. Chem."},{"issue":"36","key":"10.1016\/j.bcp.2018.06.024_b0200","doi-asserted-by":"crossref","first-page":"12684","DOI":"10.1073\/pnas.0505975102","article-title":"Three-dimensional structure of human monoamine oxidase A (MAO A): relation to the structures of rat MAO A and human MAO B","volume":"102","author":"De Colibus","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"20","key":"10.1016\/j.bcp.2018.06.024_b0205","doi-asserted-by":"crossref","first-page":"5616","DOI":"10.1021\/bi8002814","article-title":"Structural and mechanistic studies of arylalkylhydrazine inhibition of human monoamine oxidases A and B","volume":"47","author":"Binda","year":"2008","journal-title":"Biochemistry"},{"key":"10.1016\/j.bcp.2018.06.024_b0210","unstructured":"Schr\u00f6dinger Release 2016-2: LigPrep, LLC, New York, NY, 2016."},{"key":"10.1016\/j.bcp.2018.06.024_b0215","unstructured":"Schr\u00f6dinger Release 2016-2: Schr\u00f6dinger Suite 2016-2 Induced Fit Docking protocol; Glide, LLC, New York, NY, 2016; Prime, Schr\u00f6dinger LLC, New York, NY, 2016."},{"issue":"21","key":"10.1016\/j.bcp.2018.06.024_b0220","doi-asserted-by":"crossref","first-page":"6177","DOI":"10.1021\/jm051256o","article-title":"Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes","volume":"49","author":"Friesner","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2018.06.024_b0225","unstructured":"Schr\u00f6dinger Release 2016-2: Prime, LLC, New York, NY, 2016."},{"issue":"6","key":"10.1016\/j.bcp.2018.06.024_b0230","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1074\/jbc.271.6.2949","article-title":"Arachidonate and related unsaturated fatty acids selectively inactivate the guanine nucleotide-binding regulatory protein, Gz","volume":"271","author":"Glick","year":"1996","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.bcp.2018.06.024_b0235","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1046\/j.1471-4159.2003.01549.x","article-title":"Arachidonic acid and anandamide have opposite modulatory actions at the glycine transporter, GLYT1a","volume":"84","author":"Pearlman","year":"2003","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bcp.2018.06.024_b0240","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.7717\/peerj.149","article-title":"Do N-arachidonyl-glycine (NA-glycine) and 2-arachidonoyl glycerol (2-AG) share mode of action and the binding site on the beta2 subunit of GABAA receptors?","volume":"1","author":"Baur","year":"2013","journal-title":"PeerJ"},{"key":"10.1016\/j.bcp.2018.06.024_b0245","doi-asserted-by":"crossref","first-page":"340","DOI":"10.3389\/fphar.2016.00340","article-title":"Inhibitors of MAO-A and MAO-B in psychiatry and neurology","volume":"7","author":"Finberg","year":"2016","journal-title":"Front. Pharmacol."},{"issue":"12","key":"10.1016\/j.bcp.2018.06.024_b0250","doi-asserted-by":"crossref","first-page":"567","DOI":"10.3928\/00485713-20141208-06","article-title":"Monoamine oxidase inhibitors for various psychiatric disorders and conditions","volume":"44","author":"Atiwannapat","year":"2014","journal-title":"Psychiatric Ann."},{"issue":"3","key":"10.1016\/j.bcp.2018.06.024_b0255","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1017\/S1461145799001522","article-title":"Does phenylethylamine act as an endogenous amphetamine in some patients?","volume":"2","author":"Janssen","year":"1999","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2018.06.024_b0260","first-page":"137","article-title":"Modification of dopamine release by selective inhibitors of MAO-B","volume":"8","author":"Finberg","year":"2000","journal-title":"Neurobiology (Bp)"},{"key":"10.1016\/j.bcp.2018.06.024_b0265","first-page":"1","article-title":"Recognition dynamics of dopamine to human Monoamine oxidase B: role of Leu171\/Gln206 and conserved water molecules in the active site cavity","author":"Dasgupta","year":"2017","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"14","key":"10.1016\/j.bcp.2018.06.024_b0270","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1007\/s00018-006-6027-5","article-title":"The roles of cannabinoid and dopamine receptor systems in neural emotional learning circuits: implications for schizophrenia and addiction","volume":"63","author":"Laviolette","year":"2006","journal-title":"Cell. Mol. Life Sci."},{"issue":"9","key":"10.1016\/j.bcp.2018.06.024_b0275","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/nrd1495","article-title":"The endocannabinoid system and its therapeutic exploitation","volume":"3","author":"Di Marzo","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"issue":"5","key":"10.1016\/j.bcp.2018.06.024_b0280","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1523\/JNEUROSCI.5166-08.2009","article-title":"CB1 receptors mediate the analgesic effects of cannabinoids on colorectal distension-induced visceral pain in rodents","volume":"29","author":"Brusberg","year":"2009","journal-title":"J. Neurosci."},{"issue":"2","key":"10.1016\/j.bcp.2018.06.024_b0285","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ab.2006.10.039","article-title":"Quantitative profiling of endocannabinoids and related compounds in rat brain using liquid chromatography-tandem electrospray ionization mass spectrometry","volume":"360","author":"Richardson","year":"2007","journal-title":"Anal. Biochem."},{"issue":"5","key":"10.1016\/j.bcp.2018.06.024_b0290","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/sj.bjp.0707478","article-title":"Cannabinoid activation of PPAR alpha; a novel neuroprotective mechanism","volume":"152","author":"Sun","year":"2007","journal-title":"Br. J. Pharmacol."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295218302375?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295218302375?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T12:39:29Z","timestamp":1661517569000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295218302375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":58,"alternative-id":["S0006295218302375"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2018.06.024","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interactions of endocannabinoid virodhamine and related analogs with human monoamine oxidase-A and -B","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2018.06.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}